Daily Archives: September 8, 2021

Tresata Announces the Beginning of the End of Financial Crime With Free Service, BADaaS

Bad Actor Discovery as a Service (BADaaS) is the first AI-powered service that uses publicly available data on financial crime to reveal hidden connections

CHARLOTTE, N.C., Sept. 08, 2021 (GLOBE NEWSWIRE) — Tresata announced today the launch of its Regtech Cloud with the availability of Bad Actor Discovery as a Service (BADaaS). Powered by Tresata’s advanced AI systems, BADaaS offers the first free and scalable service that uses public data to identify bad actors and prevent the misuse of global financial and regulatory systems by exposing their hidden networks.

The United Nations Office on Drugs and Crime estimates $2.4 trillion is laundered through the world’s financial markets and banking systems each year, funding illicit activities such as slavery, child labor, forced prostitution, terrorism and drug trafficking. However, as the Investigative Consortium of Investigative Journalists notes—despite the known consequences and dealings of financial bad actors—these crimes often go undetected, with less than 1% of criminal funds seized by authorities annually.

This service is the first to use intelligence generated by advanced AI algorithms that scan trillions of data points across hundreds of millions of beneficial owners sourced from legal, corporate, offshore leak, and sanctions data. This allows BADaaS to identify, track, and expose hidden connections these beneficial owners have at absolute scale.

“Institutions and individuals in the financial sector aren’t the only victims of bad actors. There are significant human costs that we all bear as a result of such exploitation. It’s a global problem that will persist until we eliminate the ability of bad actors to cover their tracks,” said Abhishek Mehta, Chairman and CEO of Tresata. “We architected BADaaS to do exactly that—uncover tracks, across all available data—and we made it free, so honest hard-working professionals in governments, banks or journalism can expose these tracks, reveal suspicious connections, and join the fight to end financial crime.”

Audrey Koh, White Collar Crime & Investigations Partner at Avonhurst, an early user of BADaaS, said, “BADaaS is transformational. Traditional lookup services and existing tools are costly and struggle to keep pace with the evolving threat that is financial crime. Identifying bad actors is not enough in itself—you need to understand what their relationships are and keep track of them over time. I look forward to seeing the evolution of BADaaS’ features and functionality in the months to come.”

Tresata plans to make BADaaS a key service for its planned Regtech Cloud offering, with additional products and services slated for launch in early 2022. BADaaS is available for immediate use across all web and mobile platforms starting today.

ABOUT TRESATA
Tresata automates the analysis of data at absolute scale. Its Digital Business Engine is used by Fortune 500 companies to leverage data as an asset and create products and services that enrich the lives of all their customers.

MEDIA CONTACT:
Edward Lin, On Behalf of Tresata
E: tresata@merrittgrp.com

WillScot Mobile Mini Announces Extensions Of CEO and CFO Contracts

Tim Boswell promoted to President in addition to continuing role as Chief Financial Officer

PHOENIX, Sept. 08, 2021 (GLOBE NEWSWIRE) — The Board of Directors (“the Board”) for WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini” or the “Company”) (Nasdaq: WSC), a North American leader in modular space and portable storage solutions, today announced that its Board of Directors has extended employment arrangements with Chief Executive Officer, Brad Soultz, and Chief Financial Officer, Tim Boswell, through March 1, 2026 and July 1, 2026, respectively. Both contracts include a performance grant for each officer. Additionally, Mr. Boswell has been promoted to President and Chief Financial Officer.

Erik Olsson, Chairman of the Board, commented, “Reflecting on the tremendous shareholder value created during the first year of the transformational merger between WillScot and Mobile Mini, the Board is even more excited about the Company’s value creation runway over the next five years. To that end, the Board is thrilled to secure Brad and Tim at the helm of WillScot Mobile Mini into 2026. We are confident in their ability to continue to execute the Company’s strategy for years to come, driving value for shareholders and delivering best-in-class service and an ever-expanding value proposition to our customers.”

Brad Soultz, Chief Executive Officer, commented, “I am grateful and humbled to have the opportunity to continue to lead this great Company. Since returning WillScot to the public markets just four years ago, we have increased revenues by four times, Adjusted EBITDA by nearly six times, and market capitalization and total enterprise value by almost nine times1. We have achieved the number one market position in both modular and storage solutions, transformed our turnkey ‘Ready to Work’ value proposition through our value added products and services offerings and other initiatives, and assembled the best team in the industry, all of which are creating significant value for our shareholders. While I have thoroughly enjoyed this journey, I am even more excited about the Company’s growth and potential value creation over the next five years as we position to eclipse the $500 million free cash flow milestone we envisioned 18 months ago. As we embark on the next phase of growth, I am delighted to promote Tim Boswell to President and CFO. In addition to earning my utmost trust and respect over our last seven years of collaboration, Tim achieved the same level of admiration from both our shareholders and the broader management team. We have the right team in place to create value for our shareholders, and I am honored to work with everyone at WillScot Mobile Mini as we continue our journey together. I look forward to discussing the next steps in our growth trajectory at our Investor Day on November 8.”

Concurrent with the five-year extensions, the Board authorized special performance-based stock grants to both officers to align with shareholder value creation. The performance-based grants have no intrinsic value at grant and would not become eligible to vest unless the Company’s share price reaches at least $42.50 during the performance period. The performance-based grants begin to qualify for vesting at $42.50 per share, with maximum earning potential if the share price exceeds $60.00 per share during their respective contract extension periods. The $42.50 per share minimum performance threshold and $60.00 per share maximum performance level would represent share price increases of 50% and 112%, respectively, relative to the prior 30-day average close price of $28.37. The grants qualify for vesting once the minimum $42.50 share price threshold is achieved over their respective employment contract periods. Any grants earned during the performance period remain restricted, and vest at the end of the restricted period or upon other qualifying events. At the maximum vesting level, the total value of the grants would represent approximately 100 basis points of the incremental shareholder value created, with 750,000 shares granted to Mr. Soultz and 583,334 shares granted to Mr. Boswell. For further details for both contracts, please refer to Company filings with the SEC.

1 – Comparisons for financial metrics measured for full year as of 12/31/2017 to midpoint of 2021 guidance. Market capitalization and total enterprise value as of 11/30/2017 and 9/7/2021 and inclusive of minority interest on 11/29/2017.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. The words “estimates,” “expects,” “anticipates,” “believes,” “forecasts,” “plans,” “intends,” “may,” “will,” “should,” “shall,” “outlook” and variations of these words and similar expressions identify forward-looking statements, which are generally not historical in nature. Certain of these forward-looking statements include statements relating to value and value creation, the Company’s share price, free cash flow, and the Company’s future performance. Forward-looking statements are subject to a number of risks, uncertainties, assumptions and other important factors, many of which are outside our control, which could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. These risks include, without limitation, the risks and uncertainties described in the periodic reports we file with the SEC from time to time (including our Form 10-K/A for the year ended December 31, 2020), which are available through the SEC’s EDGAR system at www.sec.gov and on our website. Any forward-looking statement speaks only at the date which it is made, and WillScot Mobile Mini disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

About WillScot Mobile Mini Holdings Corp.

WillScot Mobile Mini Holdings trades on the Nasdaq stock exchange under the ticker symbol “WSC.” Headquartered in Phoenix, Arizona, the Company is a leading business services provider specializing in innovative flexible workspace and portable storage solutions. WillScot Mobile Mini services diverse end markets across all sectors of the economy from a network of approximately 275 branch locations and additional drop lots throughout the United States, Canada, Mexico, and the United Kingdom.

Contact Information

Investor Inquiries:

Nick Girardi

nick.girardi@willscotmobilemini.com

Media Inquiries:

Scott Junk

scott.junk@willscotmobilemini.com

People with Sleep Apnea Live Longer on CPAP in Large, Late-Breaking ResMed-Supported ALASKA Study Presented at ERS

Continued PAP use linked to 39% higher chance of survival over a 3-year period

LYON, France, Sept. 08, 2021 (GLOBE NEWSWIRE) — Using PAP (positive airway pressure) therapy as directed can significantly increase sleep apnea patients’ chances of living longer, according to a late-breaking abstract presented today at the virtual European Respiratory Society (ERS) International Congress 2021 and supported by ResMed (NYSE: RMD, ASX: RMD).

The landmark ALASKA study, “CPAP Termination and All-Cause Mortality: a French Nationwide Database Analysis,” concluded people with obstructive sleep apnea who continued PAP therapy were 39% more likely to survive than OSA patients who didn’t.1 Researchers observed over 176,000 people in France with sleep apnea over a three-year period. Study authors say the survival rate gap remained significant when accounting for patients’ ages, overall health, other pre-existing conditions, and causes of death.

“Treating sleep apnea with PAP therapy may help you live longer; that’s the key takeaway here for people with sleep apnea and their doctors,” said Adam Benjafield, study co-author and ResMed Vice President of Medical Affairs. “This finding underscores how critical it is to identify the hundreds of millions of people worldwide whose sleep apnea is undiagnosed and untreated.”

An estimated 936 million people worldwide have sleep apnea2 – including over 175 million Europeans – but over 80% remain undiagnosed.3

The ALASKA study was conducted in partnership with Professor Jean-Louis Pépin; universities of Grenoble, San Diego, and Sydney; Sêmeia; and other researchers from ResMed’s industry-academia collaboration medXcloud.

ResMed at ERS

This study is one of fourteen ERS-accepted abstracts presented, co-authored, or otherwise supported by ResMed, a global leader in sleep and respiratory care research and digitally connected therapy solutions.

On Tuesday, ResMed’s Benjafield presented the latest estimated prevalence of chronic obstructive pulmonary disease (COPD) in Europe from 2020 out to 2050. The European analysis, modelled on global burden of disease and world bank population data, reports 36.6 million Europeans have COPD as of 2020, and predicted prevalence will rise 39.6% to approximately 49.5 million by 2050.4

About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.

1 Pepin JL et al. “CPAP termination and all-cause mortality: a French nationwide database analysis.” ERS abstract, 2021
2 Benjafield AV et al. Lancet Resp Care 2019
3 Young T et al. Sleep 1997
4 Benjafield AV et al. “An estimate of the European prevalence of COPD in 2050.” ERS abstract, 2021

For media  For investors 
Jayme Rubenstein Amy Wakeham
+1 858.836.6798 +1 858.836.5000
news@resmed.com investorrelations@resmed.com


GNT Pharma Announces Approval of IND Application for the Phase III RODIN Trial of Nelonemdaz for Acute Ischemic Stroke Patients

  • PIII Study for 496 ischemic stroke patients treated with endovascular thrombectomy
  • First multi-target neuroprotectant for the intervention of ischemic brain injury
  • Safety and efficacy verified in two phase II studies for ischemic stroke patients with recanalization therapy

YONGIN, South Korea, Sept. 08, 2021 (GLOBE NEWSWIRE) —

GNT Pharma Inc. today reported that the Korea Ministry of Food and Drug Safety (MFDS) has approved the Investigational New Drug Application (IND) for a phase III study of nelonemdaz for acute ischemic stroke patients (RODIN trial). The IND approval for a more extensive phase III trial is based on the encouraging results of GNT Pharma’s earlier phase II trials. The outcomes of this phase III study will be instrumental in documenting the therapeutic potential of nelonemdaz as an effective treatment for acute ischemic stroke.

In the phase II trial completed in January 2021, iv administration of 2,750 or 5,250 mg nelonemdaz for 5 days has shown promising safety and efficacy for 209 ischemic stroke patients treated with endovascular thrombectomy within 8 hours of onset, compared to the placebo-treated group. Functional independence, activity of daily living, and early recovery were analyzed by modified Rankin Scale (mRS), Barthel index (BI), and NIH Stroke Scale (NIHSS), respectively, and all improved in nelonemdaz-treated groups. Such beneficial effects were prominent at 90 days for patients administered with 5,250 mg nelonemdaz, as shown by the marked increase of the fraction of mRS 0 (patients with no symptoms at all) from 8.2% (placebo) to 33.3% (5,250mg nelonemdaz). The phase III RODIN trial was designed to investigate beneficial effects as well as safety of 5,250 mg nelonemdaz for 496 patients with mild to severe ischemic stroke receiving endovascular thrombectomy within 12 hours of onset. Patients are enrolled at 23 university stroke centers and evaluated by mRS, NIHSS, BI, and MRI over 90 days.

“Nelonemdaz has been well demonstrated for neuroprotection effects in various animal models of stroke and shown promising efficacy in phase II clinical trials for acute ischemic stroke patients receiving reperfusion therapy. We expect the RODIN trial will confirm that nelonemdaz is safe and efficacious, providing a major new turning point in treating acute ischemic stroke patients,” said Dr. Sun-uck Kwon, Principal Investigator and Head of Stroke Center, Seoul Asan Medical Center.

The excitatory neurotransmitter glutamate is released in excess following stroke attack and causes fulminant neuronal death through overactivation of NMDA receptors. Toxic free radicals are produced over time after reperfusion and contribute to delayed ischemic-reperfusion injury. Neuroprotectants such as NMDA antagonists or antioxidants have demonstrated beneficial effects in animal models but nearly all failed in clinical trials for stroke patients, primarily due to drug-related adverse events and translational mismatch between animal models and stroke patients.

Nelonemdaz is a moderate NR2B-selective N-methyl d-aspartate (NMDA) receptor antagonist and potent spin trapper that reduces NMDA receptor-mediated excitotoxicity and oxidative stress. Compared to NMDA antagonists or antioxidants alone, nelonemdaz showed better neuroprotection and therapeutic time window in animal models of transient ischemic stroke. Safety of nelonemdaz has been demonstrated in two phase I studies for 165 healthy subjects and two phase II studies for 447 ischemic stroke patients.

Dr. Dennis W. Choi, Professor of Neurology, Stony Brook Medicine and former President of the Society for Neuroscience, who pioneered key pathological mechanisms of ischemic brain injury said, “Nelonemdaz now comes to its pivotal phase III stroke trial, backed by excellent preclinical studies and promising phase II clinical trial data.  I think nelonemdaz may prove to be the neuroprotective breakthrough that the stroke field has long been seeking.”

“While dozens of candidate neuroprotective drugs have failed in prior years, medical science has learned from these failures. Nelonemdaz leverages these new understandings, combining next generation NMDA antagonism and antioxidant properties in a single molecule. We are focusing first on stroke patients receiving endovascular thrombectomy, which has become established as a standard therapy. We are excited by the efficacy demonstrated by nelonemdaz in phase II testing and hope to conduct the phase III RODIN trial as quickly as possible”, said Dr. Byoung J Gwag, CEO of GNT Pharma.

Contact South Korea:
Byung Chul Kim
Chief Communication Officer
bckim@gntpharma.com
+82 31 8005 9910
US Office:
Dr. Eun C Park
Director, Global R&BD
ecpark@gntpharma.com
848-228-6841

VistaJet sees 86% increase in pet travel and enhances its VistaPet program with dedicated crew training and more pet partners

VistaPet

VistaJet’s enhanced crew training, now for pets

Extensive education includes courses on vital signs, animal behavior, fear of flying and CPR procedures for furry companions

London, September 8, 2021: VistaJet, the first and only global business aviation company, further expands its comprehensive VistaPet program, as the number of animals onboard soars 86% over the last two years and global pet ownership continues to rise.

Safety, security and the wellbeing of clients are fundamental for all at VistaJet. In addition to the unparalleled training with the British Butler Institute, Norland College and the Wine & Spirit Education Trust, as well as being the first in private aviation to have in-house MedAire instructors, VistaJet’s team of over 200 Cabin Hostesses now has tuition in all segments of pet first aid to ensure safety for all in-flight and that loyal companions receive the same leading service as their owners.

The extensive training program includes:

  • Pet CPR procedures from checking circulation, identifying location of the heart and optimum ratio of compressions to breath;
  • Recognizing warning signs of chocking and the best maneuvers for the situation;
  • Vital signs such as heart rate, varying pulse locations, body temperature, and mucous membrane and capillary refill time to check for circulation and levels of oxygen in the bloodstream;
  • Understanding indications of poisoning from ingested or topical, spider or insect bites, and the best treatment for each;
  • And to better understand behaviors, crew members also learn how to read body language, whether that be a friendly dog holding its ears up and a loosely wagging tail; a fearful dog with ears back and tail tucked; recognizing the difference between a rapidly twitching tail and a friendly wag; or the unpredictability of cats, gaining clues from their eyes, ears and whiskers.

Matteo Atti, EVP Marketing & Innovation at VistaJet said: “The fast increase in pet adoptions is paired with a habit of having pets as daily companions. Rabbits are a recent new breed of pet flown by VistaJet, and while dogs continue to make up the majority of animal passengers, the number of cats spiked 357% from 2019 to 2020. It’s important to continually evolve our services to offer best-in-class travel solutions to all our passengers, making them feel safe and cared for at all times. With one in four Members flying with pets, VistaJet is dedicated to ensuring dogs, cats, rabbits, birds, and any other guests benefit from the same unparalleled service their owners expect from us.”

With a 53% increase globally in new memberships during the first half of 2021, there is clear continued demand from travelers looking for a safer and more reliable flying solution. VistaJet makes flying private with pets seamless, even at destination. As customers continue to seek safe havens for the entire family, VistaJet’s Private World collection introduces the very-best pet-friendly properties around the globe. At participating Rosewood Hotels & Resorts, pets feel right at home with tailored menus and exclusive amenities, massages and cabanas for furry friends to enjoy during their stay.

VistaPet’s leading offerings also provide additional solutions for comfort and health, including:

  • Fear of flying courses for fearful ones. In partnership with The Dog House, pre-flight courses are offered to prepare for a comfortable in-flight experience. The four-week training helps dogs overcome sounds of jet engines, air pressure and the movements of air turbulence.
  • Balanced menus to keep animals healthy and hydrated. Pet passengers are served in-flight meals created in collaboration with clinical veterinarian Dr Bruce Fogle. Natural flower essences are also available to mix with pet’s drinking water to aid relaxation.
  • A safe and soft cabin. During the flight, pets can enjoy handmade Labbvenn sleep mats so they can sit down near their owners in the cabin.
  • In-flight amenity kits. The VistaPet Pochette includes bio-organic, nutritional pet food from Rockster, treats created by Michelin-starred chef Michel Roux for The Dog House, and Kibble Pet’s water-free shampoo and wipes for salon-quality fur care. For in-flight entertainment, there are Furzu rope toys.

For more information on VistaPet, please visit www.vistajet.com/pets

Information
VistaJet | press@vistajet.com

About VistaJet 
VistaJet is the first and only global business aviation company. On its fleet of over 70 silver and red business jets, VistaJet has flown corporations, governments and private clients to 187 countries, covering 96% of the world. Founded in 2004, the company pioneered an innovative business model where customers have access to an entire fleet whilst paying only for the hours they fly, free of the responsibilities and asset risks linked to aircraft ownership. VistaJet’s signature Program membership offers customers a bespoke subscription of flight hours on its fleet of mid and long-range jets, to fly them anytime, anywhere.
VistaJet is part of Vista Global Holding — the world’s first private aviation ecosystem, integrating a unique portfolio of companies offering asset-light solutions to cover all key aspects of business aviation.
More VistaJet information and news at vistajet.com

VistaJet Limited is a European air carrier that operates 9H registered aircraft under its Maltese Air Operator Certificate No. MT-17 and is incorporated in Malta under Company Number C 55231. VistaJet US Inc. is an Air Charter Broker that does not operate aircraft. VistaJet and its subsidiaries are not U.S. direct carriers. VistaJet-owned and U.S. registered aircraft are operated by properly licensed U.S. air carriers, including XOJET Aviation LLC.

Attachment

Bombardier to Hold Virtual Event Celebrating the Best of Aerospace Innovation on Tuesday, September 14, 2021

MONTRÉAL, Sept. 07, 2021 (GLOBE NEWSWIRE) — Bombardier is pleased to invite members of the international community to a special virtual event premiering at 11:00 am (EDT) on Tuesday, September 14, 2021.

The momentous virtual gathering will celebrate the best of aerospace innovation and Bombardier’s best-selling business jets.

All those wishing to join the exclusive online event may register here.

About Bombardier
Bombardier is a global leader in aviation, creating innovative and game-changing planes. Our products and services provide world-class experiences that set new standards in passenger comfort, energy efficiency, reliability and safety.

Headquartered in Montréal, Canada, Bombardier is present in more than 12 countries including its production/engineering sites and its customer support network. The Corporation supports a worldwide fleet of more than 4,900 aircraft in service with a wide variety of multinational corporations, charter and fractional ownership providers, governments and private individuals.

News and information is available at bombardier.com or follow us on Twitter @Bombardier.
Visit the Bombardier Business Aircraft website for more information on our industry-leading products and services.

Bombardier is a registered trademark of Bombardier Inc. or its affiliates.

For Information
Marie-Andrée Charron
Bombardier
marie-andree.charron@aero.bombardier.com
+1-514-855-5001 ext. 26493

Deepika Padukone to Launch Global Lifestyle Brand Rooted in India

The first category of launch will focus on Beauty and Skin Care

Deepika Padukone

LOS ANGELES, Sept. 07, 2021 (GLOBE NEWSWIRE) — Global Indian icon Deepika Padukone announced today that she has founded and is set to launch a lifestyle brand that is rooted in India but will have indispensable global reach and appeal; much like her own professional and personal journey.

The first category of launch will focus on beauty and skin care. This category specifically, while rooted in India, will be backed by science.

Padukone is one of the most admired and acclaimed actors in the world and her achievements have made her one of the most influential voices amongst global audiences and consumers in recent times.

Time Magazine named her one of the 100 Most Influential People in the World in 2018. A year later, she received the prestigious World Economic Forum Crystal Award for her leadership in raising mental health awareness. In 2018 and 2021, she featured in VARIETY’S ‘International Women’s Impact Report’ which celebrates the achievements of women in entertainment around the world.

One of the biggest brands on social media, Padukone enjoys an enormous digital footprint of more than 100 million users.

“India, I believe, has always been positioned uniquely. While we have tremendous access to the rest of the world, we are a country that is rich in values, culture and heritage; something we are extremely proud of. Therefore, our endeavour is to build a brand that is rooted in India yet global in its reach and appeal,” said Padukone.

The brand is expected to roll out in 2022.

About Deepika Padukone:

Deepika Padukone is an internationally recognized actor, producer, philanthropist, and entrepreneur. With over 30 feature films to her credit, the actor made her English language film debut as the female lead in XXX: The Return of Xander Cage, co-starring with Vin Diesel. She is also the principal of Ka Productions, the production company behind Chhapaak, in which she also starred, and upcoming films The Intern and ’83. Credits include Padmavaat which broke all box office records, as well as the award-winning and critically acclaimed films Piku and Baijaro Mastani, the highest and third highest grossing international Hindi language film releases, respectively. In 2015, she set up The Live Love Laugh Foundation, a not-for-profit whose programs and initiatives aim to destigmatize mental illness and raise awareness about the importance of mental health with a specific focus on stress, anxiety, and depression.

Global Media Contact:

Ms. Bryna Rifkin

Narrative

bryna@narrative-pr.com

Phone: +1-424-320-8024

India Media Contact:

Ms. Lavina Sachdev

Spice PR

lavina.sachdev@spiceone.net

Mr. Prabhat Choudhary

Spice PR

choudhary.prabhat@gmail.com

Related Images


Deepika Padukone
Photo Credit: Vaishnav Praveen / The House of Pixels

This content was issued through the press release distribution service at Newswire.com.

Attachment